Financial - Conglomerates
Build Your Comparison
Side-by-side financial analysisStock Comparison
ACOG vs AVXL vs SAVA vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Biotechnology
ACOG vs AVXL vs SAVA vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Financial - Conglomerates | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $98M | $232M | $64M | $7.70B |
| Revenue (TTM) | $11M | — | $0.00 | $0.00 |
| Net Income (TTM) | $-25M | $-40M | $-106M | $-327M |
| Gross Margin | 86.4% | — | — | — |
| Operating Margin | -250.1% | — | — | — |
| Total Debt | $0.00 | $0.00 | $0.00 | $110K |
| Cash & Equiv. | $66M | $103M | $129M | $357M |
ACOG vs AVXL vs SAVA vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 24 | Jun 26 | Return |
|---|---|---|---|
| Alpha Cognition Inc… (ACOG) | 100 | 95.2 | -4.8% |
| Anavex Life Science… (AVXL) | 100 | 26.4 | -73.6% |
| Cassava Sciences, I… (SAVA) | 100 | 59.4 | -40.6% |
| Praxis Precision Me… (PRAX) | 100 | 332.5 | +232.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACOG vs AVXL vs SAVA vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACOG is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- -11.3% 10Y total return vs PRAX's -36.1%
- Lower volatility, beta 1.29, current ratio 8.65x
- Beta 1.29, current ratio 8.65x
- Beta 1.29 vs SAVA's 1.92
AVXL carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 0 yrs, beta 1.77
- -34.9% revenue growth vs SAVA's -5.4%
- -35.0% ROA vs SAVA's -75.3%
SAVA is the clearest fit if your priority is growth exposure.
- EPS growth 77.6%
- 5.4% margin vs ACOG's -232.2%
PRAX is the clearest fit if your priority is momentum.
- +491.9% vs AVXL's -69.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -34.9% revenue growth vs SAVA's -5.4% | |
| Quality / Margins | 5.4% margin vs ACOG's -232.2% | |
| Stability / Safety | Beta 1.29 vs SAVA's 1.92 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +491.9% vs AVXL's -69.6% | |
| Efficiency (ROA) | -35.0% ROA vs SAVA's -75.3% |
ACOG vs AVXL vs SAVA vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ACOG vs AVXL vs SAVA vs PRAX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SAVA leads in 1 of 6 categories
ACOG leads 1 • AVXL leads 0 • PRAX leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACOG and PRAX operate at a comparable scale, with $11M and $0 in trailing revenue.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $11M | — | $0 | $0 |
| EBITDAEarnings before interest/tax | -$27M | -$39M | -$110M | -$357M |
| Net IncomeAfter-tax profit | -$25M | -$40M | -$106M | -$327M |
| Free Cash FlowCash after capex | -$30M | -$34M | -$84M | -$283M |
| Gross MarginGross profit ÷ Revenue | +86.4% | — | — | — |
| Operating MarginEBIT ÷ Revenue | -2.5% | — | — | — |
| Net MarginNet income ÷ Revenue | -2.3% | — | — | — |
| FCF MarginFCF ÷ Revenue | -2.8% | — | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -146.2% | +54.4% | +62.1% | +2.7% |
Valuation Metrics
Evenly matched — SAVA and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $98M | $232M | $64M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $32M | $129M | -$65M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -5.38x | -4.63x | -2.54x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.57x | — | — | — |
| Price / BookPrice ÷ Book value/share | 1.78x | 2.25x | 0.42x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Profitability & Efficiency
ACOG leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
AVXL delivers a -38.8% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-96 for SAVA. On the Piotroski fundamental quality scale (0–9), ACOG scores 4/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -54.1% | -38.8% | -95.8% | -43.0% |
| ROA (TTM)Return on assets | -41.8% | -35.0% | -75.3% | -40.2% |
| ROICReturn on invested capital | -32.4% | — | -6.3% | -65.0% |
| ROCEReturn on capital employed | -38.4% | -47.8% | -99.9% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 2 | 3 |
| Debt / EquityFinancial leverage | — | — | — | 0.00x |
| Net DebtTotal debt minus cash | -$66M | -$103M | -$129M | -$357M |
| Cash & Equiv.Liquid assets | $66M | $103M | $129M | $357M |
| Total DebtShort + long-term debt | $0 | $0 | $0 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | — |
Total Returns (Dividends Reinvested)
Evenly matched — ACOG and PRAX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACOG five years ago would be worth $8,873 today (with dividends reinvested), compared to $1,191 for AVXL. Over the past 12 months, PRAX leads with a +491.9% total return vs AVXL's -69.6%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs AVXL's -33.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -3.1% | -32.1% | -36.8% | -6.9% |
| 1-Year ReturnPast 12 months | -34.4% | -69.6% | -37.7% | +491.9% |
| 3-Year ReturnCumulative with dividends | -11.3% | -71.1% | -62.5% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -11.3% | -88.1% | -87.8% | -14.2% |
| 10-Year ReturnCumulative with dividends | -11.3% | -38.3% | -38.0% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -3.9% | -33.9% | -27.9% | +164.8% |
Risk & Volatility
Evenly matched — ACOG and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACOG is the less volatile stock with a 1.29 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 72.7% from its 52-week high vs AVXL's 17.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 1.77x | 1.92x | 1.55x |
| 52-Week HighHighest price in past year | $11.54 | $13.99 | $4.98 | $366.52 |
| 52-Week LowLowest price in past year | $4.50 | $2.41 | $1.27 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +54.6% | +17.9% | +26.5% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 36.8 | 42.7 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 42K | 1.0M | 134K | 396K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ACOG as "Buy", AVXL as "Buy", SAVA as "Buy", PRAX as "Buy". Consensus price targets imply 340.0% upside for AVXL (target: $11) vs 122.2% for ACOG (target: $14).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $14.00 | $11.00 | — | $607.15 |
| # AnalystsCovering analysts | 1 | 13 | 12 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
SAVA leads in 1 of 6 categories (Income & Cash Flow). ACOG leads in 1 (Profitability & Efficiency). 3 tied.
ACOG vs AVXL vs SAVA vs PRAX: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ACOG or AVXL or SAVA or PRAX a better buy right now?
Analysts rate Alpha Cognition Inc.
Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACOG or AVXL or SAVA or PRAX?
Over the past 5 years, Alpha Cognition Inc.
Common Stock (ACOG) delivered a total return of -11. 3%, compared to -88. 1% for Anavex Life Sciences Corp. (AVXL). Over 10 years, the gap is even starker: ACOG returned -11. 3% versus AVXL's -38. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACOG or AVXL or SAVA or PRAX?
By beta (market sensitivity over 5 years), Alpha Cognition Inc.
Common Stock (ACOG) is the lower-risk stock at 1. 29β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 49% more volatile than ACOG relative to the S&P 500.
04Which is growing faster — ACOG or AVXL or SAVA or PRAX?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACOG or AVXL or SAVA or PRAX?
Anavex Life Sciences Corp.
(AVXL) is the more profitable company, earning 0. 0% net margin versus -202. 2% for Alpha Cognition Inc. Common Stock — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVXL leads at 0. 0% versus -221. 7% for ACOG. At the gross margin level — before operating expenses — ACOG leads at 81. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ACOG or AVXL or SAVA or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ACOG or AVXL or SAVA or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Alpha Cognition Inc.
Common Stock (ACOG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACOG: -11. 3%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ACOG and AVXL and SAVA and PRAX?
These companies operate in different sectors (ACOG (Financial Services) and AVXL (Healthcare) and SAVA (Healthcare) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.